BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.

Researchers at the University of Maryland School of Medicine evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019

North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites

EUR 18m raised to date, with investors including Lifeline Ventures, Finnish private investors, the European Innovation Council and Business Finland

Supports the body’s natural healing response to facilitate new tendon-like tissue growth for rotator cuff repairs.1-5

PRI·MED Medical Products Continues to Supply Critical Protective Apparel to Canadian Contracts, in Addition to Supporting Additional Pandemic Demands Across the Country

Adial Pharmaceuticals, Inc. announced that it has received all necessary approvals to commence its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes.

Notes reports of potential surge in CFS-like cases worldwide as a result of COVID-19, the disease caused by the SARS-CoV-2 coronavirus

Eyecarrot Innovations Corp (2EYA:GR is pleased to announce the appointment of Dr. Jason Dyck and the appointment of Dr. Sandra Stoddard to the company’s Scientific Advisory Board.